|IFX‑1 Positive Phase IIa data in Hidradenitis Suppurativa (HS) patients
US$136 million Series D & Nasdaq IPO financings
U.S. IND opened, international Phase IIb initiated for IFX‑1 in HS patients
Strong cash position with approx. US$148 million (€123 million) at end of 2017
InflaRx (Nasdaq: IFRX), a biopharmaceutical company developing innovative therapeutics to treat life-threatening inflammatory diseases by targeting the complement system, a key component of the innate immune system, announced today financial results for the year ended December 31, 2017.
“2017 has been a transformational year for InflaRx, highlighted by multiple achievements in our pipeline and completion of two important financings that will fuel future development of our key therapeutic candidates,” said Prof. Niels C. Riedemann, Chief Executive Officer. “Specifically, we demonstrated efficacy with our lead product, IFX‑1, in a phase IIa clinical trial to treat Hidradenitis Suppurativa (HS), and completed a US$55 million private financing in October, followed by a successful US$106 million Nasdaq IPO in November. These financings provide the resources we need to drive our pipeline forward.”
In January 2018, the U.S. Food and Drug Administration approved the IND application for IFX‑1, a complement C5a inhibitor, in HS. Subsequently, InflaRx initiated phase IIb clinical testing in HS patients, and top-line data from this trial are anticipated during the first half of 2019. In 2018, the Company plans to initiate additional phase IIb clinical development of IFX‑1 in antineutrophil cytoplasmic autoantibodies (ANCA)-associated vasculitis (AAV) and in another autoimmune or inflammatory indication.
2017 Corporate highlights
- In September 2017, the company announced positive topline data from an exploratory Phase IIa clinical trial with lead compound IFX‑1, a first-in-class anti-human complement factor C5a monoclonal antibody, in patients suffering from moderate to severe Hidradenitis Suppurativa (HS), a painful, chronic and debilitating inflammatory skin disease. Assessment of the efficacy, measured by the validated and clinically relevant Hidradenitis Suppurativa Clinical Response (HiSCR) score, demonstrated a response rate of 75% (nine out of twelve patients) at the end of the treatment period and 83% (ten out of twelve) at the end of the twelve-week follow up period.
- In October 2017, InflaRx successfully closed a Series D financing and investment round of US$55 million. The round was co-led by Bain Capital Life Sciences LP, Cormorant Asset Management LLC, RA Capital Management LLC, and complemented by Black Rock.
- In November 2017, InflaRx raised US$106 million in its Nasdaq IPO (incl. green shoe). J.P. Morgan, Leerink Partners and BMO Capital Markets acted as lead managers.
- On February 6, 2018, InflaRx appointed Tony Gibney to its Board of Directors. Mr. Gibney was a life sciences-focused investment banker for 23 years at Leerink Partners, Merrill Lynch, and Lehman Brothers.
2017 Financial highlights
Cash and cash equivalents totaled €123.3 million as of December 31, 2017 compared to €29.1 million as of December 31, 2016. This increase was primarily attributable to the completion of InflaRx’ initial public offering of its common shares in November 2017 and the exercised green shoe in December 2017, as well as the primary portion of the Series D financing executed in October 2017.
Net cash used in operating activities increased from €5.0 million in the year ended December 31, 2016 to €12.2 million in the year ended December 31, 2017, mainly due to the increase of cash expenses for research and development, such as third-party expenses for manufacturing and clinical trials attributable to InflaRx’ lead program IFX‑1 and personnel expenses.
Research and development expenses increased by €9.1 million to €14.4 million in the year ended December 31, 2017 from € 5.3 million for the year ended December 31, 2016. This increase is primarily attributable to a €5.1 million increase in CRO and CMO expenses for IFX‑1 in connection with the preparation of the Phase IIb clinical trial in patients with HS and the Phase II clinical trial in patients with AAV and to a €3.4 million increase in employee-related costs associated with salaries, bonus, benefits and non-cash share-based compensation.
General and administrative expenses increased by €3.3 million to €5.1 million for the year ended December 31, 2017, from €1.8 million for the year ended December 31, 2016. This increase is primarily attributable to a €1.8 million increase in employee-related costs associated with salaries, bonus, benefits and non-cash share-based compensation. Legal, consulting and audit fees and other expenses increased by €1.0 million, which is mainly attributable to expenses incurred in connection with the IPO and Nasdaq listing.
Finance costs (net) increased by €2.8 million to €4.8 million for the year ended December 31, 2017, from €2.0 million for the year ended December 31, 2016. This increase is mainly attributable to interest expense on outstanding preferred shares issued in the Series C financing, which increased by €0.4 million to €2.2 million for the year ended December 31, 2017, from €1.8 million for the year ended December 31, 2016; and unrealized foreign exchanges losses which increased by €2.4 million to €2.4 million for the year ended December 31, 2017.
Net loss for the year 2017 was €24.2 million or €2.6 per common share, compared to €8.9 million or €3.8 per common share for the year 2016.
Additional information regarding these results is included in the notes to the consolidated financial statements as of December 31, 2017 and “Item 5. Operating and Financial Review and Prospects,” which will be included in InflaRx’s Annual Report on Form 20‑F as filed with the SEC.
More information and financial reports: 2018_03_29_InflaRx_FYR2017